$10.9 M

SYN Mkt cap, 12-Aug-2020
Synthetic Biologics Net income (Q2, 2020)-2.9 M
Synthetic Biologics EBIT (Q2, 2020)-2.9 M
Synthetic Biologics Cash, 30-Jun-20208.1 M
Synthetic Biologics EV3.4 M

Synthetic Biologics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

R&D expense

3.3m12.3m6.5m14.5m32.9m29.1m18.8m11.8m11.1m

General and administrative expense

2.6m5.0m5.8m6.0m8.1m10.1m7.5m5.7m4.6m

Operating expense total

5.9m17.3m12.3m20.5m41.0m39.3m26.3m17.6m15.7m

EBIT

(7.6m)(17.3m)(12.3m)(20.5m)(41.0m)(39.3m)(26.3m)(17.6m)(15.7m)

Interest expense

10.8m4.2m283.0k

Interest income

14.0k33.0k33.0k3.0k6.0k37.0k21.0k67.0k283.0k

Pre tax profit

(5.9m)(17.3m)(12.3m)

Income tax expense

Net Income

(8.1m)(17.1m)(12.3m)(19.8m)(43.7m)(27.3m)(15.2m)(13.4m)(15.3m)

Synthetic Biologics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.7m10.0m14.6m17.5m20.8m19.1m17.1m28.9m15.0m

Accounts Receivable

405.0k

Prepaid Expenses

16.0k2.5m1.6m1.5m9.5m827.0k593.0k1.4m

Inventories

2.5m

Current Assets

7.1m12.5m16.2m19.1m30.3m21.6m17.9m29.5m16.4m

PP&E

323.0k223.0k37.0k65.0k494.0k905.0k872.0k607.0k367.0k

Total Assets

7.5m13.4m16.3m19.1m30.8m22.5m18.8m30.1m17.2m

Accounts Payable

388.0k395.0k142.0k996.0k4.4m2.0m2.0m1.0m2.3m

Current Liabilities

417.0k395.0k1.0m9.6m15.6m19.8m9.8m3.4m5.3m

Long-term debt

473.0k

Total Debt

473.0k

Total Liabilities

417.0k395.0k1.0m9.6m15.8m20.2m10.2m3.7m5.7m

Common Stock

31.0k44.0k58.0k72.0k91.0k129.0k15.0k17.0k

Preferred Stock

Additional Paid-in Capital

58.9m81.9m96.4m110.5m160.7m175.8m192.5m230.8m232.6m

Retained Earnings

(51.9m)(68.9m)(81.3m)(101.0m)(144.8m)(172.0m)(194.2m)(219.5m)(235.5m)

Total Equity

7.1m13.0m15.2m9.6m15.0m2.2m(3.4m)14.2m(1.1m)

Financial Leverage

1.1 x1 x1.1 x2 x2.1 x10 x-5.5 x2.1 x-16.3 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.4m4.6m6.8m5.9m4.5m7.6m6.9m5.1m11.2m7.8m3.3m12.0m4.8m31.8m15.1m10.0m4.5m13.5m13.4m21.1m11.0m7.1m9.5m24.7m21.7m18.7m10.1m8.1m

Accounts Receivable

444.7k494.9k440.0k245.0k122.0k

Prepaid Expenses

75.5k123.8k83.0k94.0k151.0k2.2m1.9m1.6m1.3m1.4m1.4m1.6m7.0m10.3m7.1m5.8m3.1m3.4m1.5m1.3m606.0k535.0k559.0k860.0k1.3m1.2m1.1m897.0k

Current Assets

8.9m8.1m7.3m6.3m4.9m11.5m9.5m6.8m12.5m9.2m4.7m13.6m11.7m42.1m22.2m15.8m7.6m16.8m14.9m22.3m11.6m7.7m10.1m25.6m23.0m19.8m11.2m9.0m

PP&E

396.1k371.5k303.0k254.0k249.0k215.0k155.0k157.0k38.0k51.0k67.0k75.0k107.0k483.0k501.0k482.0k582.0k859.0k800.0k943.0k801.0k731.0k665.0k545.0k485.0k425.0k309.0k251.0k

Goodwill

178.2k178.2k

Total Assets

9.5m8.7m8.3m7.2m5.8m11.7m9.6m7.0m12.5m9.3m4.7m13.7m11.8m42.6m22.7m16.3m8.2m17.7m15.7m23.3m12.5m8.4m10.8m26.6m24.0m20.7m11.9m9.6m

Accounts Payable

286.8k193.0k316.0k278.0k390.0k196.0k213.0k584.0k773.0k1.1m873.0k1.6m8.7m6.0m4.6m4.6m4.2m3.8m1.7m1.1m1.5m1.2m879.0k766.0k1.5m2.5m1.2m1.0m

Short-term debt

258.0k268.0k

Current Liabilities

397.9k234.0k443.0k395.0k417.0k196.0k229.0k773.0k1.2m984.0k15.3m25.5m17.3m17.5m15.2m14.0m16.5m12.3m17.5m5.1m4.3m3.9m3.0m3.8m5.6m2.9m3.4m

Long-term debt

662.0k601.0k539.0k405.0k334.0k

Total Debt

662.0k601.0k539.0k663.0k602.0k

Total Liabilities

400.2k236.4k443.0k395.0k417.0k229.0k584.0k773.0k984.0k15.3m25.5m17.5m17.8m15.4m14.2m17.0m12.8m18.0m5.5m4.7m4.2m3.6m4.4m6.2m3.3m3.8m

Common Stock

28.0k28.1k33.0k33.0k33.0k45.0k45.0k45.0k58.0k58.0k58.0k73.0k73.0k91.0k91.0k91.0k92.0k118.0k128.0k129.0k129.0k130.0k5.0k16.0k17.0k17.0k18.0k19.0k

Preferred Stock

12.6m12.7m

Additional Paid-in Capital

56.7m57.1m60.9m61.8m62.3m82.6m83.0m83.4m96.8m97.7m98.3m111.7m113.3m159.6m161.8m163.5m165.1m177.3m183.8m192.0m193.2m194.2m200.8m231.8m232.2m232.5m233.7m234.9m

Retained Earnings

(47.6m)(48.7m)(53.1m)(54.9m)(56.9m)(71.2m)(73.7m)(77.0m)(85.1m)(89.7m)(94.6m)(113.4m)(127.0m)(133.8m)(155.6m)(161.3m)(169.7m)(174.9m)(179.1m)(197.0m)(196.5m)(200.8m)(204.5m)(223.4m)(227.1m)(232.4m)(239.0m)(242.3m)

Total Equity

9.1m8.4m7.9m6.9m5.4m11.5m9.4m6.4m11.8m8.1m3.8m(1.6m)(13.7m)25.1m5.0m931.0k(6.0m)761.0k3.0m(6.7m)(5.1m)(8.4m)(5.7m)10.7m7.2m2.1m(4.0m)(6.8m)

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1.2 x1.3 x-8.4 x-0.9 x1.7 x4.6 x17.5 x-1.4 x23.3 x5.3 x-3.5 x-2.4 x-1 x-1.9 x2.5 x3.3 x9.9 x-3 x-1.4 x

Synthetic Biologics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(8.1m)(17.1m)(12.3m)(19.8m)(44.8m)(27.8m)(15.5m)(13.4m)(15.4m)

Depreciation and Amortization

144.0k63.0k43.0k20.0k72.0k157.0k245.0k272.0k240.0k

Accounts Receivable

(480.0k)14.0k

Accounts Payable

153.0k7.0k(253.0k)854.0k3.4m(2.4m)27.0k(987.0k)1.3m

Cash From Operating Activities

(2.9m)(8.9m)(7.7m)(16.1m)(38.9m)(27.9m)(20.2m)(17.3m)(13.9m)

Purchases of PP&E

(10.0k)(36.0k)(48.0k)(501.0k)(569.0k)(212.0k)(7.0k)

Cash From Investing Activities

(75.0k)(10.0k)(36.0k)(48.0k)(501.0k)(569.0k)(212.0k)(7.0k)

Cash From Financing Activities

7.0m12.2m12.4m19.0m42.7m26.7m18.5m29.1m

Net Change in Cash

4.0m3.3m4.7m2.9m3.3m(1.8m)(1.9m)11.8m(13.9m)

Interest Paid

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.9m)(5.0m)(1.2m)(3.1m)(5.0m)(2.2m)(4.7m)(8.1m)(3.8m)(8.4m)(13.3m)(12.4m)(26.0m)(33.5m)(11.1m)(16.8m)(25.3m)(3.1m)(7.4m)(18.3m)(2.3m)(6.5m)(10.2m)(3.5m)(7.1m)(12.2m)(3.0m)(5.9m)

Depreciation and Amortization

108.1k132.8k20.0k39.0k51.0k11.0k23.0k33.0k3.0k7.0k13.0k8.0k19.0k39.0k37.0k57.0k111.0k57.0k116.0k172.0k71.0k141.0k207.0k62.0k122.0k182.0k58.0k116.0k

Accounts Receivable

(294.6k)(410.6k)(43.0k)(5.0k)14.0k

Accounts Payable

54.1k(39.7k)(72.0k)(110.0k)2.0k(199.0k)(182.0k)189.0k631.0k937.0k731.0k563.0k7.7m5.0m184.0k143.0k(171.0k)1.8m(270.0k)(895.0k)(527.0k)(803.0k)(1.1m)(267.0k)490.0k1.4m(1.1m)(1.3m)

Cash From Operating Activities

(1.2m)(2.1m)(1.4m)(2.7m)(4.1m)(1.7m)(3.3m)(5.0m)(3.5m)(6.8m)(11.3m)(5.5m)(12.7m)(27.9m)(5.7m)(11.5m)(17.5m)(6.0m)(11.7m)(16.3m)(6.1m)(10.4m)(14.0m)(4.2m)(7.2m)(10.3m)(5.0m)(7.0m)

Purchases of PP&E

(7.0k)(3.0k)(13.0k)(25.0k)(4.0k)(21.0k)(43.0k)(18.0k)(61.0k)(457.0k)(44.0k)(45.0k)(199.0k)(11.0k)(11.0k)(209.0k)

Cash From Investing Activities

1.2k(2.9m)(7.0k)(3.0k)(13.0k)(25.0k)(4.0k)(21.0k)(43.0k)(18.0k)(61.0k)(457.0k)(44.0k)(45.0k)(199.0k)(11.0k)(11.0k)(209.0k)

Long-term Borrowings

(24.4k)(24.4k)

Cash From Financing Activities

6.9m6.9m1.5m2.0m2.0m231.0k231.0k231.0k4.0k4.0k4.0k1.0k42.7m810.0k1.4m435.0k6.1m18.5m400.0k6.4m

Net Change in Cash

5.7m2.0m124.0k(746.0k)(2.1m)(1.4m)(3.1m)(4.8m)(3.5m)(6.8m)(11.3m)(5.5m)(12.8m)14.3m(5.7m)(10.8m)(16.3m)(5.6m)(5.7m)2.0m(6.1m)(10.0m)(7.6m)(4.2m)(7.2m)(10.3m)(5.0m)(7.0m)

Interest Paid

Income Taxes Paid

Synthetic Biologics Ratios

USDQ2, 2011

Financial Leverage

1 x